PMID: 3319676Oct 1, 1987Paper

Danazol in the treatment of myelodysplastic syndromes

European Journal of Haematology
A C BuzaidB R Greenberg

Abstract

20 patients with myelodysplastic syndromes (MDS) were treated with danazol, 800 mg daily in 4 divided doses. 18 patients were evaluable for response. 3 patients (17%), whose principal problem was anemia, responded to treatment, but only with an increase in platelet count. Responses were short-lived and lacked clinical significance. No patients with anemia or leukopenia responded to treatment and none of the 7 patients with a platelet count less than 30 x 10(9)/l responded. Danazol appears to have limited clinical utility in the treatment of MDS. However, occasional patients with thrombocytopenia may benefit.

References

Mar 1, 1986·Annals of Internal Medicine·A KornbergS Kaufman
Mar 1, 1985·Annals of Internal Medicine·Y S AhnL M Pall
Jul 1, 1985·Annals of Internal Medicine·D B CinesJ E Kiss
Jun 9, 1983·The New England Journal of Medicine·Y S AhnA G So

❮ Previous
Next ❯

Citations

May 1, 1994·British Journal of Haematology·E WattelP Fenaux
Mar 17, 2007·Cancer·Hagop KantarjianJoseph Leveque
Dec 29, 2007·American Journal of Hematology·Tatsuya ChuhjoShinji Nakao
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·T KataokaK Arihiro
Nov 1, 2002·American Journal of Hematology·Geoffrey ChanKenneth Miller
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.